Company profile
Skye Bioscience, Inc.
NASDAQ: SKYE · Healthcare · Biotechnology
#1 of 1,422 Healthcare companies by revenue
EA Score
——FH 27DQ —GM —SS 34
v0.1 · 35/100 weight · pillars only
↑ balance-sheet leverage, filing timeliness · ↓ Piotroski F, workforce scale
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$55.9M
Employees
2
as of 2026-08-21
Market cap
$9.9M
as of 2026-08-21
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Net income-$55.9M-$55.9M2025
Operating income-$58.2M-$58.2M2025
Total assets$28.3M$28.3M2025
Liabilities$8.3M$8.3M2025
Equity$20.0M$20.0M2025
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Skye Bioscience, Inc.’s financial profile?
Skye Bioscience, Inc. earned -$55.9M in FY2025 net income.
Peers · Healthcare
Conavi Medical Corp.——Advanced Biomed Inc. Common Stock——Medicure Inc.——Quince Therapeutics, Inc.——CalciMedica, Inc.——CNS Pharmaceuticals, Inc.——Neighbors
San Diego →Key facts
CEOPunit Dhillon
SectorHealthcare
IndustryBiotechnology
HeadquartersSan Diego, CA
ExchangeNASDAQ: SKYE
Employees2
IPO date2015-01-06
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.